2.1. Patients

For this prognostic study, patients were included at the Amsterdam UMC, location AMC, during November 2013 and November 2017. Inclusion criteria comprised computed tomography (CT)‐diagnosed high suspicion of resectable PDAC (Dutch Pancreatic Cancer Group criteria, Versteijne et al., 2016), scheduled for surgical exploration, a minimal eGFR of 30 mL·min⁻¹·1.73 m⁻², and no contraindications to undergo MRI scanning. The study was approved by the institutional review board of the Academic Medical Center (METC2013_254, {"type":"clinical-trial","attrs":{"text":"NCT01989000","term_id":"NCT01989000"}}NCT01989000) and performed according to the standards set by the Declaration of Helsinki. All patients gave written informed consent before the start of the study. Patients did not receive any oncological treatment before MRI scans were performed. Complete clinical follow‐up was used until September 2018.